X4 PHARMACEUTICALS, INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
X4 PHARMACEUTICALS, INC (XFOR) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price of $2.53 per share as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice · last filed 2026-08-06
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $2.53.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $2.72.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $2.52.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $3.24.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $2.53 10-Q · filed 2026-08-06 |
| 2026-03-31 | $2.72 10-Q · filed 2026-05-06 |
| 2025-12-31 | $2.52 10-K · filed 2026-03-17 |
| 2025-09-30 | $3.24 10-Q · filed 2025-11-05 |
| 2025-06-30 | $67.02 10-Q · filed 2025-08-08 |
| 2025-03-31 | $68.03 10-Q · filed 2025-05-01 |
| 2024-12-31 | $2.09 10-K · filed 2025-03-26 |
| 2024-09-30 | $2.19 10-Q · filed 2024-11-13 |
| 2024-06-30 | $2.47 10-Q · filed 2024-08-08 |
| 2024-03-31 | $2.79 10-Q · filed 2024-05-07 |
| 2023-12-31 | $3.49 10-K · filed 2024-03-21 |
| 2023-09-30 | $3.86 10-Q · filed 2023-11-09 |
| 2023-06-30 | $5.37 10-Q · filed 2023-08-10 |
| 2023-03-31 | $6.20 10-Q · filed 2023-05-04 |
| 2022-12-31 | $7.77 10-K · filed 2023-03-21 |
| 2022-09-30 | $8.52 10-Q · filed 2022-11-03 |
| 2022-06-30 | $8.59 10-Q · filed 2022-08-04 |
| 2022-03-31 | $8.84 10-Q · filed 2022-05-12 |
| 2021-12-31 | $10.05 10-K · filed 2022-03-17 |
| 2021-09-30 | $11.92 10-Q · filed 2021-11-04 |
| 2021-06-30 | $12.46 10-Q · filed 2021-08-03 |
| 2021-03-31 | $12.90 10-Q · filed 2021-05-06 |
| 2020-12-31 | $13.35 10-K · filed 2021-03-19 |
| 2020-09-30 | $14.43 10-Q · filed 2020-11-05 |
| 2020-06-30 | $14.83 10-Q · filed 2020-08-04 |
| 2020-03-31 | $16.32 10-Q · filed 2020-05-07 |
| 2019-12-31 | $17.15 10-K · filed 2020-03-12 |
| 2019-09-30 | $17.18 10-Q · filed 2019-11-07 |
| 2019-06-30 | $17.69 10-Q · filed 2019-08-07 |
| 2019-03-31 | $48.79 10-Q · filed 2019-05-15 |
| 2018-12-31 | $8.26 10-K · filed 2019-03-11 |
| 2018-09-30 | $6.41 10-Q · filed 2018-11-09 |
| 2018-06-30 | $6.06 10-Q · filed 2018-08-13 |
| 2018-03-31 | $6.84 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |